Jeisys Medical was acquired by Archimed’s MED Platform II fund Jeisys Medical’s revenues increased 44 percent annually in the three years through fiscal 2023 Archimed is an investment firm focused ...

Archimed’s private ownership of Jeisys Medical will provide the agility needed in the fast-moving skincare field as aesthetics takes market share from cosmetics, Denis Ribon, chairman and managing ...

A Aa 1,083.0 +23.94% 1,342.3 ...

Healthcare-focused private-equity firm ArchiMed has backed its first deal in Asia with yet another bet on the growing medical aesthetics market. ArchiMed is finalizing a roughly $742 million ...

Explore the Jeisys Medical stock price history with detailed daily historical prices, including open, high, low, close, and volume data. Review past trends, identify key price levels, and find the ...

Cynosure innovative products and treatments to reach more doctors and patients in Japan WESTFORD, Mass., March 18, 2022 /PRNewswire/ -- Cynosure LLC announced today that Cynosure KK (subsidiary of ...

Aa Aaaaaaa A 1,070.0 +23.49% 1,321.3 ...

Determining whether Jeisys Medical Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Jeisys Medical, Inc. manufactures and develops products used by plastic surgeons, dermatologist, physicians and health professionals. It also manufactures other medical and surgical equipment and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.